A Phase 4 interventional study of Alteplase and Alteplase in Ischemic Stroke and Alteplase Adverse Reaction, sponsored by Kafrelsheikh University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-10-29.
Sponsored by Kafrelsheikh University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing Tissue Plasminogen Activator in Ischemic Stroke — 4 open to participants now, 4 under way, 3 of them phase 3. Tissue Plasminogen Activator · Ischemic Stroke.
Among the 25 studies testing Tissue Plasminogen Activator in Ischemic Stroke, this one is the 4th largest by planned enrollment, is one of 4 that started in 2022, is one of 5 in phase 4, and was the 22nd registered.
2,625 studies on the registry are indexed under Ischemic Stroke; 982 are open to participants now.
Browse Ischemic Stroke studies →4 of the 25 studies testing Tissue Plasminogen Activator in Ischemic Stroke are open now, in 6 countries. Recruiting first, the newest first:
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–80
115 People's Hospital · Sites in Vietnam
Ages 18+
Guri Hagberg · Sites in Denmark, Norway, Sweden
Ages 18+
By country, each count listing its studies:
Tissue Plasminogen Activator: first FDA approval 1987 (ACTIVASE). What it is approved for, and how studies give it, is on its page →
Of the 668 Ischemic Stroke studies recruiting now, 402 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 4 started in 2022.
This study's planned enrollment of 716 is above the median of 120 across 1,785 interventional studies indexed under Ischemic Stroke.
Median enrollment 234 across the 25 interventional studies. Of the 19 that completed or were terminated, 2 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 25 have an industry lead sponsor. The 10 most frequent:
Kafrelsheikh University is the lead sponsor of 301 studies on the registry; 119 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
21 studies in Ischemic Stroke by Kafrelsheikh University: 12 open now, 12 under way, 11 of them phase 3. Of 8 finished, 0 (0%) have results posted.
Among the 21 studies in Ischemic Stroke by Kafrelsheikh University, this one is the 12th largest by planned enrollment, is one of 9 that started in 2022, is one of 3 in phase 4, reaches primary completion later than 0 of the 11 other live ones, and was the 20th registered.
Kafrelsheikh University’s Ischemic Stroke studies by the year they started, since 2019.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing Tissue Plasminogen Activator in Ischemic Stroke, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Kafrelsheikh University’s 21 in Ischemic Stroke:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The investigators evaluated the impact of AF on different subtypes of post-alteplase hemorrhagic transformation of brain infarction.
Investigators conducted a prospective cohort study between July 2021 and July 2023. They screened 1550 patients who presented with AIS and received alteplase and included 716 AIS patients who met the inclusion criteria and were diagnosed based on a thorough clinical assessment, including a detailed medical history, physical examination, and specific brain imaging results and treated with alteplase within four and half hours of stroke onset.
The investigators assessed the patients' follow-up brain imaging to detect the subtypes of hemorrhagic transformation after receiving alteplase.
The study consisted of two distinct groups. The first group consisted of 454 patients who did not experience hemorrhagic infarction, while the second group comprised 262 patients who experienced hemorrhagic infarction.
The investigators evaluated whether the characteristics of ischemic stroke patients, door-to-needle time, and stroke risk factors different types of AF were predictive variables for different subtypes of post-alteplase hemorrhagic transformation of brain infarction.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
262 acute ischemic stroke (AIS) patients who had a hemorrhagic transformation of brain infarction after 24-36 hours of receiving alteplase.
Drug: Alteplase
454 acute ischemic stroke (AIS) patients did not have a hemorrhagic transformation of brain infarction after 24-36 hours of receiving alteplase
Drug: Alteplase
Following the guidelines set by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit
Also known as: group A
Following the guidelines set by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit
Also known as: group B
the rate of each AF type in the hemorrhagic infarction type 1 group compared to non HT group
The investigators will evaluate the rate of each AF type in the hemorrhagic infarction type 1 group compared to non HT group
Time frame: 48 days
the rate of each AF type in the hemorrhagic infarction type 2 group compared to non HT group
The investigators will evaluate the rate of each AF type in the hemorrhagic infarction type 2 group compared to non HT group
Time frame: 48 hours
the rate of each AF type in the parenchymal haematoma type 1 group compared to non HT group
The investigators will evaluate the rate of each AF type in the parenchymal haematoma type 1 group compared to non HT group
Time frame: 48 hours
the rate of each AF type in the parenchymal haematoma type 2 group compared to non HT group
The investigators will evaluate the rate of each AF type in the parenchymal haematoma type 2 group compared to non HT group
Time frame: 48 hours
Plan to share: No — All the data supporting this research's findings may be available from the principal investigator, Mohamed G. Zeinhom, upon reasonable request.
Ran from Jul 2022 to primary completion in Jul 2024, 24 months.
Of 76 non-industry phase 4 interventional studies under Ischemic Stroke, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 42. This study's 24 months is below that.
Counting every sponsor, half of 85 studies reached it within 31 months; a quarter within 24 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tissue Plasminogen Activator